Background/Purpose: In the SELECT-GCA phase 3 trial, treatment of patients with GCA with upadacitinib 15 mg (UPA15) demonstrated superior rates of disease remission, fewer disease flares, and reduced glucocorticoid (GC) use compared with placebo (PBO).1 The current study analyzed the 2-year outcomes in this trial. Methods: SELECT-GCA included a 52-week randomized, PBO-controlled period 1 and … Continue reading Efficacy and Safety of Upadacitinib in Giant Cell Arteritis: 2-Year Results From the Re-Randomized, Double-Blind SELECT-GCA Phase 3 Trial